MedPath

Sarepta Therapeutics

Sarepta Therapeutics logo
🇺🇸United States
Ownership
Private, Public
Established
1980-01-01
Employees
1.3K
Market Cap
$13.4B
Website
http://www.sarepta.com
Introduction

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

Phase 3
Terminated
Conditions
Duchenne Muscular Dystrophy
Interventions
First Posted Date
2018-05-22
Last Posted Date
2023-08-21
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
171
Registration Number
NCT03532542
Locations
🇺🇸

Children's Hospital of Wisconsin, Corporate Center Suite 540, Milwaukee, Wisconsin, United States

🇺🇸

Neuromuscular Research Center, Phoenix, Arizona, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

and more 47 locations

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)

Phase 1
Completed
Conditions
Muscular Dystrophy, Duchenne
Interventions
First Posted Date
2017-12-18
Last Posted Date
2022-07-06
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
15
Registration Number
NCT03375255
Locations
🇺🇸

Neuromuscular Research Center, Sacramento, California, United States

🇺🇸

NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States

🇺🇸

Rare Disease Research, LLC, Atlanta, Georgia, United States

and more 5 locations

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Phase 1
Completed
Conditions
Duchenne Muscular Dystrophy
First Posted Date
2017-12-15
Last Posted Date
2024-11-14
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
4
Registration Number
NCT03375164
Locations
🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

Phase 2
Completed
Conditions
Duchenne Muscular Dystrophy
Interventions
First Posted Date
2017-07-17
Last Posted Date
2021-12-09
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
15
Registration Number
NCT03218995
Locations
🇧🇪

Universitair ziekenhuis Gent, Gent, Belgium

🇫🇷

Armand-Trousseau Hospital, Paris, France

🇮🇹

Site Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy

and more 1 locations

rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies

Phase 1
Completed
Conditions
Dysferlinopathy
Interventions
First Posted Date
2016-03-16
Last Posted Date
2021-05-13
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
2
Registration Number
NCT02710500
Locations
🇺🇸

Nationwide Children's Hosptial, Columbus, Ohio, United States

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

Phase 1
Completed
Conditions
Duchenne Muscular Dystrophy
Interventions
Drug: Placebo
First Posted Date
2015-08-21
Last Posted Date
2021-05-17
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
12
Registration Number
NCT02530905
Locations
🇺🇸

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

🇺🇸

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

🇺🇸

Kennedy Krieger Institute, Baltimore, Maryland, United States

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

Phase 3
Active, not recruiting
Conditions
Duchenne Muscular Dystrophy
Interventions
First Posted Date
2015-07-16
Last Posted Date
2024-12-16
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
228
Registration Number
NCT02500381
Locations
🇺🇸

Neuromuscular Research Center, Phoenix, Arizona, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

David Geffen School of Medicine, UCLA, Los Angeles, California, United States

and more 72 locations

Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

Phase 2
Completed
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
First Posted Date
2015-04-17
Last Posted Date
2021-01-25
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
33
Registration Number
NCT02420379
Locations
🇺🇸

Neuromuscular Research Center of Arizona, Phoenix, Arizona, United States

🇺🇸

Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

🇺🇸

University of California, Davis Medical Center, Sacramento, California, United States

and more 10 locations

Phase I/II Study of SRP-4053 in DMD Patients

Phase 1
Completed
Conditions
Duchenne Muscular Dystrophy
Interventions
Drug: Placebo
First Posted Date
2014-12-08
Last Posted Date
2020-10-19
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
39
Registration Number
NCT02310906
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇫🇷

Institute de Myologie, Paris, France

🇮🇹

Policlinico Universitario A Gemelli, Rome, Italy

and more 2 locations

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

Phase 2
Completed
Conditions
Muscular Dystrophy, Duchenne
Interventions
First Posted Date
2014-11-10
Last Posted Date
2020-03-30
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
24
Registration Number
NCT02286947
Locations
🇺🇸

Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

🇺🇸

University of California, Davis Medical Center, Sacramento, California, United States

🇺🇸

University of Iowa Children's Hospital, Iowa City, Iowa, United States

and more 6 locations
© Copyright 2025. All Rights Reserved by MedPath